Interpace Biosciences, Inc. (MUN:PF42)

Market Cap	47.22M +799.3%
Revenue (ttm)	32.98M -17.5%
Net Income	20.93M +266.7%
EPS	0.75 -36.5%
Shares Out	n/a
PE Ratio	2.26
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.710
Previous Close	1.710
Day's Range	1.710 - 1.710
52-Week Range	1.070 - 1.710
Beta	n/a
RSI	100.00
Earnings Date	Apr 14, 2026

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy ri...

• Industry: Medical Laboratories
• Founded: 1986
• Employees: 102
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: PF42

Financial Performance

In 2025, Interpace Biosciences's revenue was $38.73 million, a decrease of -17.47% compared to the previous year's $46.93 million. Earnings were $24.58 million, an increase of 293.96%.

Financial numbers in USD